Forte Biosciences Shares Surge 36% on Positive Phase 1b Vitiligo Trial Results
FBRX•Forte Biosciences shares jumped 35.9% after reporting positive Phase 1b vitiligo trial results, with its FB-102 topical candidate demonstrating consistent re-pigmentation and favorable safety in dose-escalation cohorts. The company indicated plans to initiate an expanded Phase 2 study later in 2026 to further evaluate efficacy and dosing.
1. Phase 1b Vitiligo Trial Outcomes
Forte’s FB-102 topical candidate demonstrated consistent re-pigmentation in dose-escalation cohorts of the Phase 1b vitiligo study, with a majority of participants showing measurable melanocyte activity. No serious adverse events were reported, underscoring a favorable safety and tolerability profile across all dosing levels.
2. Market Reaction and Next Steps
Shares climbed 35.9% on the positive preliminary data, with trading volume surging to more than three times the 30-day average. The company plans to launch an expanded Phase 2 trial in late 2026 to refine dosing regimens and confirm efficacy in a larger patient population.
